JP2006514035A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514035A5
JP2006514035A5 JP2004562291A JP2004562291A JP2006514035A5 JP 2006514035 A5 JP2006514035 A5 JP 2006514035A5 JP 2004562291 A JP2004562291 A JP 2004562291A JP 2004562291 A JP2004562291 A JP 2004562291A JP 2006514035 A5 JP2006514035 A5 JP 2006514035A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
exendin
peptide
composition according
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004562291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514035A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/040504 external-priority patent/WO2004056313A2/en
Publication of JP2006514035A publication Critical patent/JP2006514035A/ja
Publication of JP2006514035A5 publication Critical patent/JP2006514035A5/ja
Pending legal-status Critical Current

Links

JP2004562291A 2002-12-17 2003-12-17 心不整脈の予防および治療 Pending JP2006514035A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43450802P 2002-12-17 2002-12-17
US43488802P 2002-12-19 2002-12-19
PCT/US2003/040504 WO2004056313A2 (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias

Publications (2)

Publication Number Publication Date
JP2006514035A JP2006514035A (ja) 2006-04-27
JP2006514035A5 true JP2006514035A5 (https=) 2006-11-30

Family

ID=32685317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004562291A Pending JP2006514035A (ja) 2002-12-17 2003-12-17 心不整脈の予防および治療

Country Status (4)

Country Link
EP (1) EP1610811A4 (https=)
JP (1) JP2006514035A (https=)
AU (1) AU2003297356A1 (https=)
WO (1) WO2004056313A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2007022123A2 (en) * 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
DK1888103T3 (da) * 2005-04-11 2012-04-23 Amylin Pharmaceuticals Inc Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
WO2007139941A2 (en) * 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
WO2009033739A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
CN104039344A (zh) * 2011-10-28 2014-09-10 法瑞斯生物技术有限公司 用于防止心脏缺血-再灌注损伤的多肽
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
CN108939052B (zh) * 2018-09-04 2021-03-16 江苏省中医药研究院 艾塞那肽在制备预防或治疗房颤的药物中的用途
CN110551203B (zh) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 一种艾塞那肽类似物
TW202140058A (zh) * 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
EP1054594B1 (en) * 1998-02-13 2007-07-04 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
CN103356996A (zh) * 2000-05-19 2013-10-23 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
NZ519752A (en) * 2000-10-20 2005-04-29 Amylin Pharmaceuticals Inc Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
WO2002085406A1 (en) * 2001-04-24 2002-10-31 Restoragen, Inc. Methods and compositions for treating conditions associated with insulin resistance

Similar Documents

Publication Publication Date Title
JP2006514035A5 (https=)
KR101996739B1 (ko) 글루카곤 및 glp-1 수용체의 공-효능제
AU2016244202B2 (en) Pharmaceutical composition for treating a metabolic syndrome
DE60016393T2 (de) Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe
Chrysant et al. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors
EP3080150B1 (en) Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
AU2015243611B2 (en) Dual GLP-1 / glucagon receptor agonists derived from exendin-4
KR100518046B1 (ko) Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
EP3080154B1 (en) Dual glp-1/gip receptor agonists
US7259136B2 (en) Compositions and methods for treating peripheral vascular disease
US7790681B2 (en) Treatment of cardiac arrhythmias with GLP-1 receptor ligands
EP1330261B1 (en) Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
Jakubowska et al. The road towards triple agonists: glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and glucagon receptor-an update
JP2005535569A5 (https=)
Mudaliar et al. Incretin therapies: effects beyond glycemic control
WO2004056313A2 (en) Prevention and treatment of cardiac arrhythmias
WO2015086732A1 (en) Exendin-4 peptide analogues
Holst Incretin therapy for diabetes mellitus type 2
KR101661332B1 (ko) 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
WO2017074798A2 (en) Long-acting co-agonists of the glucagon and glp-1 receptors
KR20220119475A (ko) 글루카곤 및 glp-1 수용체의 스테이플화된 트리아졸 공-효능제
M McCormick et al. Cardiac protection via metabolic modulation: an emerging role for incretin-based therapies?
Bulushova et al. Incretin analogues in the therapy of type 2 diabetes and obesity
Alonso et al. GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives
Papazafiropoulou et al. Cardiovascular effects of glucagon-like peptide 1